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Background: Volume estimation of subcortical grey matter structures is becoming a 
field of interest in multiple sclerosis (MS). The goal of this study was to compare 
volume estimations for subcortical structures obtained with the NeuroQuant® and 
FIRST in a cohort of clinically isolated syndrome (CIS) patients. 
Material and methods: 115 CIS patients were analyzed. Structural images were 
acquired on a 3.0 T system using a sagittal 3D T1-weighted gradient-echo (MPRAGE) 
sequence (TR=2300 ms, TE=3000 ms, voxel size=1.0x1.0x1.2mm3). Volumes for 
subcortical structures were obtained with Neuroquant® and FIRST -following the 
described methodology; total intracranial volumes were also obtained. The Intraclass 
Correlation Coefficient (ICC) between the two estimated volumes (NeuroQuant® and 
FIRST) was calculated for each of the following structures: (right and left) thalamus, 
caudate, putamen, pallidum, hippocampus and amygdala. The total intracranial 
volume was also considered. For each structure, the percentage difference of the 
volume calculated with FIRST in relation to the volume estimated by NeuroQuant® was 
also calculated. 
Results: The ICC was below 0.45 for the following structures: pallidum (ICC left=0.25, 
ICC right=0.27), amygdala (ICC left=0.29, ICC right=0.35) and total intracranial volume 
(ICC=0.44). The ICC ranged between 0.45 and 0.65 for the caudate (ICC left=0.46, ICC 
right=0.61) and thalamus (ICC left=0.55, ICC right=0.64); and it was higher than 0.65 for 
the hippocampus (ICC left=0.67, ICC right=0.76) and putamen (ICC right=0.79, ICC 
left=0.83). FIRST estimated volumes were systematically lower than the volumes 
obtained with NeuroQuant®, except for the pallidum (both right and left), where FIRST 
volumes were on average 70% higher than NeuroQuant® volumes. FIRST 
underestimations ranged between 1% and 12% for (both right and left) thalamus, 
caudate, putamen, hippocampus and total intracranial volume; and between 20% and 
28% for right and left amygdala.  
Conclusions: Structures showing largest disagreement between the two methods were 
the smallest ones (pallidum and amygdala). For the other subcortical grey matter 
regions, the agreement on the estimated volumes was moderate to strong. 
 
Disclosure: Novartis supported software analysis. 
Deborah Pareto has received speaking honoraria from Novartis and Genzyme. 
F. Xavier Aymerich has nothing to disclose. 
Jaume Sastre-Garriga has received compensation for consulting services and speaking 
honoraria from Merck-Serono, Biogen-Idec, Teva, Sanofi-Aventis and Novartis. 
Cristina Auger has received speaking honoraria from Novartis and Genzyme. 
Mar Tintoré has received compensation for consulting services and speaking honoraria 
from Bayer-Schering, Merck-Serono, Biogen-Idec, Teva, Sanofi-Aventis, and Novartis.  
Xavier Montalban has received speaking honoraria and travel expenses for scientific 
meetings, has been a steering committee member of clinical trials or participated in 
advisory boards of clinical trials in the past with Bayer Schering Pharma, Biogen Idec, 
EMD Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva 
Pharmaceuticals and Almirall. 
Alex Rovira serves on scientific advisory boards for Biogen Idec, Novartis, Genzyme, 
and OLEA Medical, and has received speaker honoraria from Bayer, Genzyme, Sanofi-
Aventis, Bracco, Merck-Serono, Teva Pharmaceutical Industries Ltd, OLEA Medical, 
Stendhal, Novartis and Biogen Idec.  
 
Travel Grant / Young Scientific Investigator's Sessions: I will not apply for Travel Grant 
or Young Scientific Investigator's Sessions 
Preferred Presentation Type: Poster presentation only 
 
